MDxHealth SA has announced that it has signed a distribution agreement with Teva Pharmaceuticals to offer its SelectMDx(TM) for Prostate Cancer test to Teva's urology customers throughout Israel. Under the terms of the three-year agreement, Teva Pharmaceuticals will be the exclusive distributor of the SelectMDx for Prostate Cancer test in Israel. Samples will be sent to MDxHealth's clinical diagnostic laboratory in Nijmegen, The Netherlands for analysis. Teva will reimburse MDxHealth for all the testing services.
Dr. Jan Groen, Chief Executive Officer of MDxHealth, stated: "We are pleased to expand our longstanding partnership with Teva and allow patients in Israel to access SelectMDx, a test which is ideally suited to address an unmet need in urology. SelectMDx provides a non-invasive, 'liquid biopsy' test which improves patient selection for prostate biopsy."
Sapir Avinoam, VP and General Manager of Teva Israel, added: "The SelectMDx test opens up the opportunity to address a broader segment of patients at risk for prostate cancer and being considered for an invasive biopsy procedure. The test further complements our portfolio of molecular tests and services, allowing us to better serve our physician base and improve patient outcomes."